PD-0332991 |
PALBOCICLIB |
IBRANCE |
UNII-G9ZF61LE7G |
PD 332991 |
IBRANCE® |
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-{[5-(PIPERAZIN-1-YL)PYRIDIN-2-YL]AMINO}PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE |
PD 0332991 |
PD0332991 |
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-(5-PIPERAZIN-1-YLPYRIDIN-2-YLAMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE |
rxcui:1601374 |
chemidplus:571190-30-2 |
chembl:CHEMBL189963 |
pubchem.compound:5330286 |
drugbank:09073 |
Drug Categories | cyclin-dependent kinases, antagonists & inhibitors |
Drug Class | Kinase Inhibitors |
FDA Approval | Breast cancer (HR+, HER2-) |
Drug Class | Small molecule inhibitor |
Pharmaceutical Developer | Pfizer |
Source Reported Drug Name(s) | PD0332991 |
Drug Class | CDK/Rb Inhibitor |
Drug Groups | investigational |
Drug Categories | bcrp/abcg2 inhibitors |
Drug Categories | bcrp/abcg2 substrates |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | kinase inhibitor |
Drug Categories | narrow therapeutic index drugs |
Drug Categories | oct1 inhibitors |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
n/a |
combination therapy | Palbociclib + Trametinib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
inhibitor (inhibitory) |
Reported Cancer Type | Melanoma |
Mechanism of Interaction | CDK4/cyclin D1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
n/a |
Drug family | CDK4/6 inhibitor |
Alteration | CCND2:amp |
inhibitor (inhibitory) |
Mechanism of Interaction | CDK6/cyclin D1 inhibitor |
Direct Interaction | yes |
PALBOCICLIB | DrugBank Drug Name |
571190-30-2 | CAS Number |
Ibrance | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
IBRANCE | Trade Name |
Drug Class | Small molecule inhibitor |
FDA Approval | Breast cancer (HR+, HER2-) |
PD 0332991 | PubChem Drug Name |
11431660 | PubChem Drug ID |
Palbociclib | Drug Trade Name |
Drug Class | CDK/Rb Inhibitor |
Source Reported Drug Name(s) | PD0332991 |
Pharmaceutical Developer | Pfizer |
PD0332991 | Development Name |
Drug Class | Kinase Inhibitors |
CHEMBL189963 | ChEMBL Drug ID |
PALBOCICLIB | GuideToPharmacology Ligand Name |